Apr. 22 at 1:25 PM
$IVDA you’re not wrong that they’re bleeding money, the cost structure is clearly an issue.
But shutting down offices isn’t really a fix, it simply just cuts off potential revenue while most of those public company costs (audits, legal, compliance, Nasdaq fees, etc.) still exist no matter what.
I think the bigger point is this: those offices aren’t the core problem… underperformance is.
Like you said, Iveda Taiwan is doing 80–85% of the revenue (
$4.5M), which basically proves the model can work when it’s executed properly.
So the goal shouldn’t be to shrink the footprint, it should be to replicate what’s working.
If they can develop even one or two of the new regions to operate like Taiwan, now you’re talking about multiple revenue streams each doing a few million a year.
That’s how you grow into profitability, not by cutting your way there.
📈
